David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

"Aethlon Medical treats first subject with Hemopurifier device in Australia" was originally created and published by Medical ...

A 19-year-old is celebrating being cancer-free – a year after he was told that there was no hope and to “go home and make ...

Aethlon announces first patient enrolled and treated with the Hemopurifier at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital: San Diego Friday, January 31, 2025, 1 ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

Adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.

Australian researchers achieve a breakthrough in improving breast cancer cure rates, offering new hope for patients worldwide ...